2023
Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults
Kopel H, Nguyen V, Boileau C, Bogdanov A, Winer I, Ducruet T, Zeng N, Bonafede M, Esposito D, Martin D, Rosen A, Van de Velde N, Vermund S, Gravenstein S, Mansi J. Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults. Vaccines 2023, 11: 1711. PMID: 38006043, PMCID: PMC10675676, DOI: 10.3390/vaccines11111711.Peer-Reviewed Original ResearchCOVID-19-related hospitalizationRelative vaccine effectivenessOutpatient visitsPrimary care electronic health recordsCOVID-19-related outcomesVaccine-induced protectionMedical claims dataCOVID-19 vaccineSARS-CoV-2Electronic health recordsVaccine effectivenessVaccine recipientsMRNA vaccinesBivalent vaccineBaseline differencesStudy populationClaims dataOmicron variantComparative effectivenessHospitalizationPropensity scoreVaccineOlder adultsHealth recordsVisitsAge-dependent impairment in antibody responses elicited by a homologous CoronaVac booster dose
Filardi B, Monteiro V, Schwartzmann P, do Prado Martins V, Zucca L, Baiocchi G, Malik A, Silva J, Hahn A, Chen N, Pham K, Pérez-Then E, Miric M, Brache V, Cochon L, Larocca R, Della Rosa Mendez R, Silveira D, Pinto A, Croda J, Yildirim I, Omer S, Ko A, Vermund S, Grubaugh N, Iwasaki A, Lucas C, Initiative Y, Vogels C, Breban M, Koch T, Chaguza C, Tikhonova I, Castaldi C, Mane S, De Kumar B, Ferguson D, Kerantzas N, Peaper D, Landry M, Schulz W. Age-dependent impairment in antibody responses elicited by a homologous CoronaVac booster dose. Science Translational Medicine 2023, 15: eade6023. PMID: 36791210, DOI: 10.1126/scitranslmed.ade6023.Peer-Reviewed Original ResearchConceptsBooster doseAntibody responseNeutralization titersVirus-specific IgG titersOlder adultsAntiviral humoral immunityPlasma antibody responsesHigh-risk populationSARS-CoV-2 spikeYears of ageAge-dependent impairmentHeterologous regimensBooster dosesBooster vaccineCoronaVac vaccineIgG titersProtective immunityHumoral immunityHumoral responseCoronaVacOmicron waveBooster strategyAge groupsEarly controlVaccine
2022
COVID-19 Vaccine Hesitancy among Adolescents: Cross-Sectional School Survey in Four Chinese Cities Prior to Vaccine Availability
Rehati P, Amaerjiang N, Yang L, Xiao H, Li M, Zunong J, Wang L, Vermund SH, Hu Y. COVID-19 Vaccine Hesitancy among Adolescents: Cross-Sectional School Survey in Four Chinese Cities Prior to Vaccine Availability. Vaccines 2022, 10: 452. PMID: 35335083, PMCID: PMC8952375, DOI: 10.3390/vaccines10030452.Peer-Reviewed Original ResearchVaccine hesitancyCOVID-19 vaccine hesitancyLimited health literacyNovel coronavirus disease (COVID-19) pandemicCross-sectional surveyCoronavirus disease (COVID-19) pandemicLow risk awarenessMultivariable analysisMean ageVaccination awarenessVaccination experienceEffective vaccineDoctor's recommendationVaccine preparednessMultinomial logistic regressionVaccine confidenceHealth literacyVaccine availabilityVaccination concernsVaccine resistanceVaccine accessLogistic regressionEmergency useDisease pandemicVaccineNeutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
Pérez-Then E, Lucas C, Monteiro VS, Miric M, Brache V, Cochon L, Vogels CBF, Malik AA, De la Cruz E, Jorge A, De los Santos M, Leon P, Breban MI, Billig K, Yildirim I, Pearson C, Downing R, Gagnon E, Muyombwe A, Razeq J, Campbell M, Ko AI, Omer SB, Grubaugh ND, Vermund SH, Iwasaki A. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination. Nature Medicine 2022, 28: 481-485. PMID: 35051990, PMCID: PMC8938264, DOI: 10.1038/s41591-022-01705-6.Peer-Reviewed Original ResearchConceptsTwo-dose regimenOmicron variantVaccine boosterMRNA vaccinesNeutralization activityDelta variantTwo-dose mRNA vaccinesVirus-specific antibody levelsSARS-CoV-2 Omicron variantMRNA vaccine boosterNeutralization of OmicronNumerous spike mutationsSARS-CoV-2 DeltaPotent neutralization activityInfection-induced immunityCOVID-19 vaccineBNT162b2 boosterBooster vaccinationPrime vaccinationAntibody levelsAntibody titersHumoral immunityImmune escapeInactivated vaccinesVaccine
2017
The case for integrated human papillomavirus vaccine and HIV prevention with broader sexual and reproductive health and rights services for adolescent girls and young women
Narasimhan M, Pedersen H, Ogilvie G, Vermund SH. The case for integrated human papillomavirus vaccine and HIV prevention with broader sexual and reproductive health and rights services for adolescent girls and young women. Transactions Of The Royal Society Of Tropical Medicine And Hygiene 2017, 111: 141-143. PMID: 28673020, PMCID: PMC6257065, DOI: 10.1093/trstmh/trx032.Peer-Reviewed Original Research
2005
Parents’/guardians’ willingness to vaccinate their children against genital herpes
Liddon N, Pulley L, Cockerham WC, Lueschen G, Vermund SH, Hook EW. Parents’/guardians’ willingness to vaccinate their children against genital herpes. Journal Of Adolescent Health 2005, 37: 187-193. PMID: 16109337, DOI: 10.1016/j.jadohealth.2005.05.030.Peer-Reviewed Original ResearchConceptsHSV-2Type 2 vaccineLogistic regression modelsParents/guardiansInfluenza shotSTD vaccinesCorrelates of intentionGenital herpesMajority of parentsVaccine acceptanceDisease vaccineVaccinationLogistic regressionOptimal timingFuture interventionsVaccineAppropriate timingSexual activityTelephone surveyChildrenParents' acceptanceInterventionOne-thirdDescriptive statisticsOverall attitude
1994
The role of prevention research in HIV vaccine trials.
Vermund SH. The role of prevention research in HIV vaccine trials. AIDS Research And Human Retroviruses 1994, 10 Suppl 2: s303-5. PMID: 7865326.Peer-Reviewed Original ResearchConceptsVaccine trialsLarge-scale vaccine trialsHIV vaccine efficacy trialsPrevention researchVaccine efficacy trialsHIV vaccine trialsPrevention clinical trialsHIV prevention researchSexual transmissionClinical trialsEfficacy trialsNeedle useHIV researchInfectious diseasesBlood contaminationPotential trial sitesTrialsNational InstituteObservational researchTrial sitesSame criteriaPrevention technologiesAllergyVaccineInfection